Medigene präsentiert auf folgenden wissenschaftlichen Konferenzen
Die Medigene AG (Medigene oder das "Unternehmen", FWB: MDG1, Prime Standard) ein immunonkologisches Plattformunternehmen…
Die Medigene AG (Medigene oder das "Unternehmen", FWB: MDG1, Prime Standard) ein immunonkologisches Plattformunternehmen…
- Synergies between the recombinant T cell technologies of Medigene and self-delivering RNAi technologies from RXi Pharm…
Monetization of last remaining legacy product essentially completes Medigene's transformation into a pure-play, clinical…
Medigene AG (MDG1, Frankfurt, Prime Standard, TecDAX) announces that a scientific article on a method to identify T cell…
The Executive Management Board of Medigene AG (FSE: MDG1, Prime Standard, TecDAX) with the approval of the Company's Sup…
Medigene AG (FSE: MDG1, Prime Standard, TecDAX), will demonstrate the use of its automated high-throughput screening (HT…
- Automated in vitro testing could reveal better neoantigens that activate more effective killer T cell responses - Two…
. - First poster reports of a semi-automated method for the isolation and initial characterization of neoantigen-specif…
Medigene AG (FSE: MDG1, Prime Standard, TecDAX) today announced the appointment of eight leading experts to its new immu…
Growing revenues from core business immunotherapies, clinical trial application for second immunotherapy submitted, fina…